NVL-655 clinical trials

Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors

This program offers people with advanced ALK-positive lung cancer or other ALK-positive tumours an opportunity to receive an investigational medicine called neladalkib (NVL-655). It is for those who can't join a regular trial and have run out of other good treatment options.